In brief: Ipamorelin is a synthetic pentapeptide first described as a growth-hormone secretagogue. Early laboratory studies examined its ability to stimulate growth-hormone release through a receptor pathway now associated with the ghrelin receptor, also called GHSR-1a. Published research includes preclinical experiments, a small short-term study in healthy male volunteers and a later Phase II study in postoperative patients. These studies do not establish muscle gain, fat loss, recovery, anti-ageing effects or long-term safety.
Research-use notice: This article is provided for general laboratory education. Helix Bio products are supplied strictly for research purposes only and are not intended for human or veterinary use, consumption, diagnosis, treatment or any clinical application. Nothing here is dosing, administration, treatment or medical advice.
What is Ipamorelin?
Ipamorelin is a synthetic peptide made from five amino-acid-derived building blocks. The sequence reported in the original pharmacology paper is Aib–His–D-2-Nal–D-Phe–Lys-NH2. Because it contains five residues, it is described as a pentapeptide. Several of those components are modified or non-standard residues, and the C-terminus is amidated. These structural choices help distinguish Ipamorelin from naturally occurring ghrelin and from longer growth-hormone-releasing peptides.
The compound was developed during research into growth-hormone secretagogues: molecules that can trigger growth-hormone release through receptor signalling rather than supplying growth hormone itself. That distinction is fundamental. Ipamorelin is not growth hormone, and a short-term hormone response measured in an experiment is not the same thing as demonstrating a lasting physiological or clinical outcome.
For the current Helix Bio product specification and documentation status, see the Ipamorelin 5mg research listing. A product listing is not evidence of regulatory approval, clinical suitability or a completed laboratory result.
Why is Ipamorelin called a growth-hormone secretagogue?
A secretagogue is a substance studied for its ability to promote secretion. In this context, the measured output is growth hormone released from pituitary somatotroph cells. The word describes an experimental mechanism; it does not state that a compound is an approved medicine or that changing one laboratory measurement produces a particular health, performance or body-composition result.
The terminology has also evolved. The 1998 Ipamorelin paper referred to a “GHRP-like receptor” or “GHRP receptor.” The receptor is now commonly described as the ghrelin receptor or growth-hormone secretagogue receptor type 1a, abbreviated GHSR-1a. It belongs to the G-protein-coupled receptor family and is expressed in tissues including the pituitary and hypothalamus.
Ipamorelin and the GHSR-1a receptor
GHSR-1a is a seven-transmembrane G-protein-coupled receptor. Ghrelin is its endogenous ligand, while multiple synthetic peptide and non-peptide compounds have been investigated as receptor agonists. Receptor activation can initiate intracellular signalling associated with growth-hormone release, but receptor biology is more complex than a simple on-and-off switch.
Ligands can differ in binding, potency, efficacy, signalling preference, exposure and activity in different experimental systems. A result from isolated pituitary cells cannot automatically be transferred to an intact animal, and an acute response in a small human study cannot establish a long-term outcome. The receptor pathway provides a biological explanation for what researchers measured; it does not provide proof for every claim made about the compound online.
It is also important not to treat Ipamorelin as interchangeable with growth-hormone-releasing hormone, commonly shortened to GHRH. GHRH acts through the GHRH receptor. Ipamorelin is studied through the ghrelin or growth-hormone secretagogue receptor pathway. The two systems can converge on growth-hormone release while remaining pharmacologically distinct.
This is why Ipamorelin and CJC-1295 Without DAC are discussed as two separate research components in the HULK STACK research guide. Evidence about either ingredient cannot automatically be treated as evidence about the exact combined formulation.
What did the original Ipamorelin research examine?
The 1998 preclinical pharmacology paper
The foundational paper described Ipamorelin in primary rat pituitary cells and in rat and swine models. In the cell system, the researchers reported growth-hormone release with potency and efficacy in the same broad range as GHRP-6 under the study conditions. Antagonist experiments supported activity through a GHRP-like receptor rather than the GHRH receptor.
The animal experiments also examined selectivity. In swine, GHRP-2 and GHRP-6 increased ACTH and cortisol under the reported conditions, whereas Ipamorelin did not produce levels significantly different from those observed after GHRH stimulation. This is the origin of the widely repeated description of Ipamorelin as “selective.”
That conclusion must remain attached to its evidence. The selectivity comparison came from particular cell and animal experiments, measured selected hormones and used specific experimental conditions. It does not mean “side-effect free,” and it does not establish comprehensive selectivity, safety or clinical benefit in humans.
The 1999 human PK/PD study
A later dose-escalation study examined Ipamorelin pharmacokinetics and pharmacodynamics in healthy male volunteers. Eight subjects were included at each of five intravenous infusion levels. Researchers measured Ipamorelin concentrations and circulating growth hormone.
The paper reported dose-proportional pharmacokinetic behaviour over the tested range, a terminal half-life of about two hours and a single episode of growth-hormone release. The growth-hormone peak occurred at roughly 0.67 hours and then declined towards negligible concentrations at all tested levels. The investigators used these measurements to construct a population PK/PD model.
This study is evidence of a short-term measured response under controlled conditions. It did not examine self-administration, repeated consumer use, muscle growth, fat reduction, exercise recovery, sleep, ageing, long-term endocrine effects or clinical effectiveness for those purposes. It also involved intravenous infusion in a small, selected population, which limits how far its findings can be generalised.
The 2014 Phase II postoperative study
Ipamorelin was later studied as a ghrelin-receptor agonist in a multicentre, double-blind, placebo-controlled Phase II trial involving adults after bowel resection. This was a very different research question: whether receptor stimulation could help manage postoperative ileus.
The trial enrolled 117 participants, with 114 included in the safety and modified intention-to-treat populations. The key efficacy endpoint was time from the first study dose to tolerating a standardised solid meal. The median was 25.3 hours in the Ipamorelin group and 32.6 hours with placebo, but the difference was not statistically significant. The researchers also reported no significant differences in the key or secondary efficacy analyses.
This result is useful precisely because it shows why receptor activity and early pharmacology cannot substitute for outcome evidence. A plausible biological pathway does not guarantee that a later controlled trial will meet its endpoint.
What does the published evidence not establish?
The available publications are frequently stretched beyond their designs. None of the three core studies described above establishes that Ipamorelin:
- increases muscle mass or strength in humans;
- reduces body fat or causes weight loss;
- improves exercise recovery, sleep or wellbeing;
- reverses ageing or produces “anti-ageing” effects;
- is safe for long-term or unsupervised use;
- has the same effect when combined with another peptide;
- is suitable for human or veterinary consumption.
Animal findings can identify mechanisms and generate hypotheses, but species, exposure, experimental setting and outcome measurement all matter. Likewise, a transient change in circulating growth hormone is a pharmacodynamic observation—not proof of a downstream body-composition or health outcome.
Does “selective” mean safe?
No. In pharmacology, selective is a comparative and conditional term. It may describe a preference for one receptor, pathway or measured output over another within a defined experiment. Selectivity can vary with concentration, tissue, species, assay design and the endpoints chosen by investigators.
The original Ipamorelin work compared growth-hormone release with a limited set of other hormonal measurements in preclinical models. It did not test every biological pathway or establish long-term human safety. A compound can appear selective in one assay while still having unmeasured effects elsewhere.
The responsible conclusion
Ipamorelin has a defined early pharmacology record and limited human research. The literature supports discussion of its structure, receptor pathway and measured experimental responses. It does not support converting those observations into claims about physique, recovery, anti-ageing effects, long-term safety or the performance of an untested combination.
Research materials and documentation
When evaluating any research peptide, keep compound identity, chromatographic purity and quantitative content separate. A matching mass can support identity; an HPLC main-peak percentage can describe detected chromatographic purity under a stated method; and a quantitative assay addresses how much analyte is present on its stated basis. No single number answers every question.
Use the Helix Bio guide to reading a peptide Certificate of Analysis and check the current report-library status. A report marked pending is not a completed or passed result. Product name, strength and batch or lot details must match before a document is connected to a material.
Storage is a separate control. Temperature, moisture, light, oxygen exposure and repeated temperature changes can affect research materials after manufacture or testing. Read the general peptide storage and stability guide, while giving priority to the label and batch-specific documentation.
Ipamorelin and anti-doping rules
The World Anti-Doping Agency’s 2026 Prohibited List names Ipamorelin among growth-hormone secretagogues and their mimetics in class S2.2.4. That class is prohibited at all times, both in and out of competition. Athletes and support personnel should use the current official WADA list and the rules applicable to their sport rather than relying on a product description or general article.
Frequently asked questions
Is Ipamorelin a peptide?
Yes. It is a synthetic pentapeptide containing five amino-acid-derived residues, including modified residues, with an amidated C-terminus.
Is Ipamorelin the same as growth hormone?
No. Ipamorelin is described as a growth-hormone secretagogue because it was studied for signalling associated with growth-hormone release. It is not growth hormone itself.
What receptor is associated with Ipamorelin?
Ipamorelin is commonly discussed as an agonist of the ghrelin receptor, also called the growth-hormone secretagogue receptor type 1a or GHSR-1a. The earliest paper used the older description “GHRP-like receptor.”
Does Ipamorelin research prove muscle gain or fat loss?
No. The core published studies discussed here examined receptor pharmacology, short-term pharmacokinetic and hormone measurements, and postoperative ileus. They did not establish muscle gain or fat-loss outcomes.
Has the exact HULK STACK combination been clinically tested?
The cited Ipamorelin studies did not test the Helix Bio formulation containing Ipamorelin and CJC-1295 Without DAC. Evidence about individual ingredients cannot automatically be transferred to a specific combination.
Is Ipamorelin prohibited in sport?
Yes. The WADA 2026 Prohibited List names Ipamorelin among growth-hormone secretagogues and mimetics prohibited at all times.
Where can I find Helix Bio research information?
The peptide glossary explains common terminology, while the research peptide collection provides current product specifications and availability. These resources are for laboratory research information only.
Sources and further reading
- Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998.
- Gobburu JV et al. Pharmacokinetic-pharmacodynamic modeling of Ipamorelin in human volunteers. Pharmaceutical Research. 1999.
- Beck DE et al. Randomized proof-of-concept study of Ipamorelin for postoperative ileus. International Journal of Colorectal Disease. 2014.
- NCBI Gene: GHSR growth hormone secretagogue receptor.
- World Anti-Doping Agency: 2026 Prohibited List.
For research purposes only — not for human consumption.
This article provides general educational information about published research. It does not provide dosing, administration, treatment or clinical-use guidance.
Last reviewed: 26 October 2026.